Imaging of drug and metabolite distribution by MS: case studies.
Analysis of drug and metabolite distribution is essential for understanding of the mechanisms underlying the pharmacological or toxicological effects. MS imaging (MSI) can visualize the distribution of drugs or biological molecules in tissue sections without radiolabeling, and distinguish between the distribution of a drug and that of its metabolites in tissue sections. Therefore, it is expected to be a potent imaging technique for drug distribution studies. This article includes cases in which MSI was used to analyze drug and metabolite distribution, and discusses the impact of data obtained by MSI in drug discovery and development.
Research Laboratory for Development, Shionogi & Co. Ltd., Futaba 3-1-1, Toyonaka, Osaka 561-0825, Japan.
Nozomi
N
Takai
Research Laboratory for Development, Shionogi & Co. Ltd., Futaba 3-1-1, Toyonaka, Osaka 561-0825, Japan.
Yukari
Y
Tanaka
D000818:Animals; D001345:Autoradiography; D004285:Dogs; D024841:Fluoroquinolones / Q000032:analysis / Q000378:metabolism; D000077341:Lapatinib; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008168:Lung / Q000378:metabolism / Q000473:pathology; D051379:Mice; D000077266:Moxifloxacin; D004364:Pharmaceutical Preparations / Q000032:analysis / Q000378:metabolism*; D011799:Quinazolines / Q000032:analysis / Q000378:metabolism; D011817:Rabbits; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D016593:Terfenadine / Q000032:analysis / Q000378:metabolism; D014018:Tissue Distribution; D051598:Whole Body Imaging
D024841:Fluoroquinolones; D004364:Pharmaceutical Preparations; D011799:Quinazolines; D000077341:Lapatinib; D016593:Terfenadine; D000077266:Moxifloxacin